Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
Key facts
- Who runs it
- ALPS Biotech CO. LTD
- Where
- Taiwan1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 16 Sept 2024
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Antrodia cinnamomea Products
- Record updated
- 10 December 2024
Who can take part
- Age
- 30 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged 30 to 70 years, whose native language is Chinese
- Patients diagnosed with Spinocerebellar Ataxia
- Subjects with a score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale)
- Individuals who can read and write in Chinese and communicate in Chinese
- Agree to participate in the study
Who cannot take part
- Patients who have taken Antrodia cinnamomea products within the last 6 months prior to the trial
- Patients with severe systemic diseases, such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable malignancies
- Pregnant women and breastfeeding mothers
- Patients with other factors that prevent them from continuing to participate in this study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 30 and 70 years old?
This trial is currently available in Taiwan.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to assess the effect of Antrodia cinnamomea on clinical symptoms in spinocerebellar ataxia patients. To investigate the advancements in neurodegenerative diseases.
The 2 groups in the trial
- Stage I: Antrodia Cinnamomea Products + Stage II: PlaceboExisting treatment, for comparison
Crossover design: During 0 week\~8 weeks is Stage I : • Dietary Supplement: Antrodia Cinnamomea Products During 16 weeks\~ 24 weeks is Stage II: • Dietary Supplement: Placebo
Treatment: Antrodia cinnamomea Products
- Stage I: Placebo + Stage II: Antrodia Cinnamomea ProductsPlacebo, for comparison
Crossover design: During 0 week\~8 weeks is Stage I : • Dietary Supplement: Placebo During 16 weeks\~ 24 weeks is Stage II: • Dietary Supplement: Antrodia Cinnamomea Products
Treatment: Antrodia cinnamomea Products
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT06633003, who can take part
- Record updated
- 10 December 2024